4-nitrophenethylsulfonamide | 90007-78-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-nitrophenethylsulfonamide
• 英文别名: 4-Nitro-phenethylsulfonsaeure-amid；2-(4-nitro-phenyl)-ethanesulfonic acid amide；2-(4-Nitro-phenyl)-aethansulfonsaeure-amid；2-(4-Nitrophenyl)ethane-1-sulfonamide；2-(4-nitrophenyl)ethanesulfonamide
• CAS: 90007-78-6
• 化学式: C₈H₁₀N₂O₄S
• mdl: MFCD12190408
• 分子量: 230.244
• InChiKey: UFKZHNIFLPRVPB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  114
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-nitrophenethylsulfonamide 在 palladium on activated charcoal sodium hydroxide 、 氢气 作用下， 以 丙酮 为溶剂， 生成 N'-(4-Amino-phenethylsulfonyl)-N-butyl-harnstoff
  参考文献：
  名称：

  一些新的磺酰脲的合成。

  摘要：

  DOI：

  10.1021/jm00341a007
• 作为产物：
  描述：

  4-硝基苯乙烷磺酰氯 在 氨 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 2.0h， 生成 4-nitrophenethylsulfonamide
  参考文献：
  名称：

  5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE

  摘要：

  本发明针对当前对选择性和强效蛋白酪氨酸激酶抑制剂的需求，提供对c-fms激酶的强效抑制剂。本发明涉及以下式I的新化合物： 或其盐、对映体、互变异构体、结晶、多晶型、无定形、溶剂化物、水合物、酯、前药或代谢物形式，其中A、Y、Z、R 101 和R 200 在说明书中有描述。

  公开号：

  US20080114007A1

文献信息

• 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE
  申请人：Player R. Mark

  公开号：US20080114007A1

  公开（公告）日：2008-05-15

  The invention addresses the current need for selective and potent protein tyrosine kinase inhibitors by providing potent inhibitors of c-fms kinase. The invention is directed to the novel compounds of Formula I: or a salt, stereoisomer, tautomer, crystalline, polymorph, amorphous, solvate, hydrate, ester, prodrug or metabolite form thereof, wherein A, Y, Z, R 101 and R 200 are described in the specification.

  本发明针对当前对选择性和强效蛋白酪氨酸激酶抑制剂的需求，提供对c-fms激酶的强效抑制剂。本发明涉及以下式I的新化合物： 或其盐、对映体、互变异构体、结晶、多晶型、无定形、溶剂化物、水合物、酯、前药或代谢物形式，其中A、Y、Z、R 101 和R 200 在说明书中有描述。
• Synthesis and Evaluation of Potent and Selective β₃ Adrenergic Receptor Agonists Containing Acylsulfonamide, Sulfonylsulfonamide, and Sulfonylurea Carboxylic Acid Isosteres
  作者：David E. Uehling、Kelly H. Donaldson、David N. Deaton、Clifton E. Hyman、Elizabeth E. Sugg、David G. Barrett、Robert G. Hughes、Barbara Reitter、Kim K. Adkison、Mary E. Lancaster、Frank Lee、Robert Hart、Mark A. Paulik、Bryan W. Sherman、Timothy True、Conrad Cowan

  DOI：10.1021/jm0101500

  日期：2002.1.1

  Starting from phenethanolamine aniline leads 3a and 3b, we have identified a series of functionally potent and selective beta(3) adrenergic receptor (AR) agonists containing acylsulfonamide, sulfonylsulfonamide, or sulfonylurea groups within the aniline phenethanolamine series. In beta(3) beta(2), and beta(1) AR cAMP functional assays, 3a and other right-hand side (RHS) carboxylate analogues were found to be full agonists that were modestly selective against beta(1) or beta(2) ARs, while analogues lacking RHS acid functionality were active at beta(3) AR but not selective. Replacement of the carboxylate with acylthiazole and acylmethylsulfone gave potent, but only modestly selective, compounds. Increasing the size of the RHS sulfonamide substituent with phenyl or p-toluene afforded compounds with good potency and functional selectivity (beta(3) AR pEC(50) greater than 8; beta(1) and beta(2) AR selectivity greater than 40- and 500-fold, respectively). Our SAR studies suggest that the potency and selectivity profile of the best analogues reported here is a result of both the steric bulk and acidity of the RHS sulfonamide NH group. Although all of the analogues had a pharmacokinetic half-life of less than 2 h, acylsulfonamides 43 and 44 did show moderately low clearance in dogs. These two compounds were further evaluated by thermographic imaging in mice and were found to produce a robust thermogenic response via oral administration.
• The Preparation of Some Amino Sulfonamides
  作者：Ellis Miller、James M. Sprague、L. W. Kissinger、Lane F. McBurney

  DOI：10.1021/ja01865a053

  日期：1940.8
• [EN] ARYLETHANOLAMINE DERIVATIVES AND THEIR USE AS AGONISTS OF ATYPICAL BETA-ADRENOCEPTORS<br/>[FR] DERIVES D'ARYLETHANOLAMINE ET LEUR UTILISATION EN TANT QU'AGONISTES DES BETA-RECEPTEURS ADRENERGIQUES ATYPIQUES
  申请人：GLAXO GROUP LIMITED

  公开号：WO1997021666A1

  公开（公告）日：1997-06-19

  (EN) The present invention relates to phenethanolamine derivatives of formula (I), wherein R1 represents an aryl group optionally substituted by one or more substituents selected from halogen, hydroxy, C1-6alkoxy, C1-6alkyl, nitro, cyano, hydroxymethyl and trifluoromethyl; R2 represents hydrogen or C1-6alkyl; R3 represents a group (A) where the aromatic ring may be optionally substituted by up to four substituents selected from C1-6alkyl, halogen, trifluoromethyl, and C1-6alkoxy; R4 represents hydrogen, or C1-6alkyl; R5 represents CO2R8, C1-6alkylCO2R16, CONR9R10, NHCONR11R12, SO2NHR13, P(O)(OR14)2, SO3H, C1-6alkylSO3H, NHSO2R15, NHCOR17 or tetrazol-5-yl; R6 and R7 independently represent hydrogen, C1-6alkyl, trifluoromethyl, CN, OH, CO2R18, CH2CO2R19, or R6 and R7 form a 5-6 membered cycloalkyl ring; R8 represents hydrogen, or C1-6alkyl; R9 represents hydrogen, C1-6alkyl, or C1-6alkylOR20; R10, R11, R12, R14-R16, and R18-R20 each independently represent hydrogen, or C1-6alkyl; R13 represents C1-6alkyl or trifluoromethyl; R17 represents C1-6alkyl or trifluoromethyl; with the proviso that when R6 and R7 are both hydrogen, R8 is other than hydrogen; and physiologically acceptable derivatives thereof; to processes for their preparation; and their use in the treatment of conditions susceptible of amelioration by an atypical beta-adrenoceptor agonist.(FR) La présente invention se rapporte à des dérivés de phénéthanolamine de la formule (I), ainsi qu'à des dérivés de ceux-ci, acceptables sur le plan physiologique. Dans cette formule, R1 représente un groupe aryle éventuellement substitué par un ou plusieurs substituants choisis parmi halogène, hydroxy, alcoxy C1-6, alkyle C1-6, nitro, cyano, hydroxyméthyle et trifluorométhyle; R2 représente hydrogène ou alkyle C1-6; R3 représente un groupe (A) où le noyau aromatique peut être éventuellement substitué par au maximum quatre substituants choisis parmi alkyle C1-6, halogène, trifluorométhyle et alcoxy C1-6, R4 représente hydrogène ou alkyle C1-6, R5 représente CO2R8, alkyle C1-6CO2R16, CONR9R10, NHCONR11R12, SO2NHR13, P(O)(OR14)2, SO3H, alkyle C1-6SO3H, NHSO2R15, NHCOR17 ou tétrazol-5-yle, R6 et R7 représentent indépendamment hydrogène, alkyle C1-6, trifluorométhyle, CN, OH, CO2R18, CH2CO2R19, ou bien R6 et R7 forment un noyau cycloalkyle possédant 5 à 6 chaînons, R8 représente hydrogène ou alkyle C1-6, R9 représente hydrogène, alkyle C1-6 ou alkyle C1-6OR20, R10, R11, R12, R14-R16 et R18-R20 représentent chacun indépendamment hydrogène ou alkyle C1-6, R13 représente alkyle C1-6 ou trifluorométhyle, R17 représente alkyle C1-6 ou trifluorométhyle, à la condition que lorsque R6 et R7 représentent tous deux hydrogène, R8 ne représente pas hydrogène. On décrit également des procédés de préparation de ces dérivés ainsi que leur utilisation dans le traitement d'états pathologiques susceptibles d'être améliorés par un agoniste des bêta-récepteurs adrénergiques atypiques.
• The Synthesis of Some New Sulfonylureas
  作者：Bernard Loev、Kenneth M. Snader、Donald T. Walz

  DOI：10.1021/jm00341a007

  日期：1963.9